- Home
- JTAI vs APM Comparison
JTAI vs APM Comparison
Compare JTAI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- APM
- Stock Information
- Founded
- JTAI 2018
- APM 2010
- Country
- JTAI United States
- APM United Kingdom
- Employees
- JTAI N/A
- APM N/A
- Industry
- JTAI Blank Checks
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- APM Health Care
- Exchange
- JTAI Nasdaq
- APM Nasdaq
- Market Cap
- JTAI 7.1M
- APM 8.3M
- IPO Year
- JTAI N/A
- APM 2018
- Fundamental
- Price
- JTAI $6.59
- APM $1.10
- Analyst Decision
- JTAI
- APM
- Analyst Count
- JTAI 0
- APM 0
- Target Price
- JTAI N/A
- APM N/A
- AVG Volume (30 Days)
- JTAI 13.3M
- APM 175.0K
- Earning Date
- JTAI 03-31-2025
- APM 12-20-2024
- Dividend Yield
- JTAI N/A
- APM N/A
- EPS Growth
- JTAI N/A
- APM N/A
- EPS
- JTAI N/A
- APM 0.00
- Revenue
- JTAI $15,028,926.00
- APM N/A
- Revenue This Year
- JTAI $21.49
- APM $157,729.10
- Revenue Next Year
- JTAI $10.05
- APM N/A
- P/E Ratio
- JTAI N/A
- APM $424.93
- Revenue Growth
- JTAI 46.66
- APM N/A
- 52 Week Low
- JTAI $2.30
- APM $0.46
- 52 Week High
- JTAI $315.00
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- JTAI 58.27
- APM 45.00
- Support Level
- JTAI $3.90
- APM $1.02
- Resistance Level
- JTAI $11.77
- APM $1.80
- Average True Range (ATR)
- JTAI 1.29
- APM 0.14
- MACD
- JTAI 0.65
- APM -0.02
- Stochastic Oscillator
- JTAI 45.30
- APM 9.63
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.